GlassScriptPhysician profile
Ma Francesca Chamian
NPI 1902088503
$16,766.08
in general payments reported to CMS, 2019-2025
44 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $1,639 · 2021: $2,463 · 2022: $2,733 · 2023: $2,979 · 2024: $2,726 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,261 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,260.80 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,922.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,132.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,076.08 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,071.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,007.04 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $860.70 | 2020-2025 | Nexletol |
| Pfizer INC. | $711.02 | 2019-2025 | |
| Abbvie INC. | $698.65 | 2020-2025 | Qulipta, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $675.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $633.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.54 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $422.08 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $320.27 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $233.51 | 2019-2025 | Jynarque |
| Sanofi-Aventis U.S. LLC | $209.52 | 2019-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $199.98 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $182.97 | 2019-2022 | |
| Lucid Diagnostics INC. | $156.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.12 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $151.97 | 2019-2024 | Veozah |
| Dexcom, INC. | $145.37 | 2022-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $123.30 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.95 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $100.40 | 2021 | |
| Exact Sciences Corporation | $97.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $96.01 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $90.70 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $88.42 | 2024 | Korlym |
| Horizon Therapeutics Plc | $70.50 | 2022-2023 | Krystexxa |
| Halozyme INC | $56.71 | 2023 | |
| Merck Sharp & Dohme LLC | $55.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.65 | 2019-2023 | Cuvitru |
| Endo Pharmaceuticals INC. | $40.31 | 2019 | |
| Daiichi Sankyo INC. | $33.68 | 2019-2024 | Injectafer |
| Nevro Corp. | $32.39 | 2023 | Senza |
| Medicure Pharma INC. | $31.04 | 2021 | |
| Shield Therapeutics INC | $23.58 | 2025 | |
| Boston Scientific Corporation | $20.58 | 2020 | |
| Seqirus USA INC | $19.16 | 2025 | Flucelvax, Fluad |
| Currax Pharmaceuticals LLC | $17.01 | 2021 | |
| Intra-Sana Laboratories | $15.61 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Bioventus LLC | $15.53 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ma Francesca Chamian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.